SEC Company Response from PDS Biotechnology Corp (PDSB) (CIK 0001472091) (PDSB) — Sep 28, 2015
PDS Biotechnology Corp (PDSB) (CIK 0001472091)
Date: Sept. 28, 2015 · CIK: 0001472091 · Accession: 0001567619-15-001271
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-206416
Letter
Re: Edge Therapeutics, Inc. Registration Statement on Form S-1 (No. 333-206416)
September 28, 2015
Via EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, NE
Washington, D.C. 20549
Attention: Jeffrey P. Riedler, Assistant Director
Ladies and Gentlemen:
Pursuant to Rule 461 of the Securities Act of 1933, as amended (the “Act”), Leerink Partners LLC and Credit Suisse Securities (USA) LLC, as representatives of the several underwriters, hereby join Edge Therapeutics, Inc., in requesting that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 3:00 p.m. Eastern time on September 30, 2015, or as soon thereafter as possible.
Pursuant to Rule 460 under the Act, we wish to advise you that we have distributed approximately 2,375 copies of the Preliminary Prospectus dated September 21, 2015 (the “Preliminary Prospectus”) through the date hereof to underwriters, dealers, institutions and others.
This is to further advise you that the underwriters have complied and will continue to comply with Rule 15c2-8 under the Securities Exchange Act of 1934, as amended, in connection with the above-referenced Preliminary Prospectus.
Very truly yours,
LEERINK PARTNERS LLC
Show Raw Text
CORRESP 1 filename1.htm September 28, 2015 Via EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Attention: Jeffrey P. Riedler, Assistant Director Re: Edge Therapeutics, Inc. Registration Statement on Form S-1 (No. 333-206416) Ladies and Gentlemen: Pursuant to Rule 461 of the Securities Act of 1933, as amended (the “Act”), Leerink Partners LLC and Credit Suisse Securities (USA) LLC, as representatives of the several underwriters, hereby join Edge Therapeutics, Inc., in requesting that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 3:00 p.m. Eastern time on September 30, 2015, or as soon thereafter as possible. Pursuant to Rule 460 under the Act, we wish to advise you that we have distributed approximately 2,375 copies of the Preliminary Prospectus dated September 21, 2015 (the “Preliminary Prospectus”) through the date hereof to underwriters, dealers, institutions and others. This is to further advise you that the underwriters have complied and will continue to comply with Rule 15c2-8 under the Securities Exchange Act of 1934, as amended, in connection with the above-referenced Preliminary Prospectus. Very truly yours, LEERINK PARTNERS LLC By: J. Eric Anderson Name: J. Eric Anderson Title: Chief Compliance Officer CREDIT SUISSE SECURITIES (USA) LLC By: /s/ Nathanael J. Chang Name: Nathanael J. Chang Title: Director [Signature Page to Underwriters’ Acceleration Request]